Get the Stockscreener App
12.73
1.55%
-0.20
After Hours:
12.73
Myriad Genetics Inc Stock (MYGN) Latest News
Myriad Genetics and CancerCARE for Life Announce Agreement - GlobeNewswire
Major Healthcare Partnership: Myriad's Advanced Cancer Risk Test Now Available to Million-Plus Patients - StockTitan
Predictive Genetic Counselling Market Size, Trends, - openPR
Myriad Genetics and Lumea Collaborate to Enhance Access to - GlobeNewswire
Myriad Genetics secures patents for cancer MRD tests - Investing.com India
Myriad Genetics Get 2 Patents for Molecular Residual Disease Assay -February 05, 2025 at 05:41 pm EST - Marketscreener.com
Myriad Genetics secures patents for cancer MRD tests By Investing.com - Investing.com South Africa
Myriad Genetics Announces Two New Patents Granted For Its Molecular Residual Disease (MRD) Assay - Marketscreener.com
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay - GlobeNewswire
Revolutionary Cancer Testing Integration: Myriad Genetics Slashes Result Times to Under 10 Days - StockTitan
Pancreatic Cancer Market Size USD 5.7 Billion, Opportunities, - openPR
Piper Sandler Cuts Myriad Genetics (NASDAQ:MYGN) Price Target to $14.00 - MarketBeat
Fifth Third Bancorp Sells 23,296 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Sold by Nisa Investment Advisors LLC - Defense World
Piper Sandler Issues Pessimistic Forecast for Myriad Genetics (NASDAQ:MYGN) Stock Price - Defense World
Myriad Genetics (NASDAQ:MYGN) Price Target Cut to $18.00 by Analysts at The Goldman Sachs Group - MarketBeat
Myriad Genetics Unveils Groundbreaking Eight Weeks’ - GlobeNewswire
Revolutionary Prenatal Test Gives Parents Answers 2 Weeks Earlier Than Ever Before - StockTitan
DNA Diagnostics Market Booming Demand: Growth Trends, Share, - openPR
Cancer Diagnostics Market Top Companies StudyDanaher - openPR
Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
(MYGN) Trading Advice - Stock Traders Daily
Myria and Beacher’s Madhouse to Bring an Unforgettable Spectacle to New Orleans During Big Game Weekend - GlobeNewswire Inc.
Why Is Larry Robbins Bullish on Myriad Genetics, Inc. (MYGN) Now? - Yahoo Finance
MYGN Stock Gains Following the Launch of Know More Sooner - MSN
Myriad Genetics (NASDAQ:MYGN) Reaches New 12-Month LowHere's Why - MarketBeat
FY2024 EPS Forecast for Myriad Genetics Increased by Analyst - Defense World
Myriad Genetics stock hits 52-week low at $12.16 amid market challenges - Investing.com
Myriad Genetics Introduces Online Prenatal Genetic Testing Resource - Yahoo Finance
FY2024 EPS Estimates for Myriad Genetics Raised by Analyst - MarketBeat
Predictive Genetic Testing and Consumer Genomics Market Research 2024-2034: Expanding DTC Genetic Testing, Consumer Interest in Personalized Healthcare, Awareness of Early Detection and Prevention - Yahoo Finance
Genomic Biomarker Market Growth in Future Scope 2025-2032 | - openPR
Myriad Genetics Doubles Cancer Testing Rates with Revolutionary Online Screening Tool - StockTitan
Myriad Genetics plummets 20% as UnitedHealth changes GeneSight coverage - MSN
Myriad Genetics (NASDAQ:MYGN) Updates FY 2024 Earnings Guidance - MarketBeat
Stephens Reaffirms Equal Weight Rating for Myriad Genetics (NASDAQ:MYGN) - MarketBeat
Myriad Genetics stock hits 52-week low at $12.85 amid market challenges - Investing.com Australia
RSI Alert: Myriad Genetics (MYGN) Now Oversold - Nasdaq
Myriad Genetics: Navigating Through A Setback (NASDAQ:MYGN) - Seeking Alpha
Brokerages Set Myriad Genetics, Inc. (NASDAQ:MYGN) Target Price at $24.27 - MarketBeat
Demystifying Myriad Genetics: Insights From 6 Analyst Reviews - Benzinga
Myriad Genetics, Inc. Provides Unaudited Earnings Guidance for the Fourth Quarter and Full-Year Ended December 31, 2024 and Full-Year of 2025 - Marketscreener.com
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Rating of “Hold” from Analysts - Defense World
Myriad Genetics sees FY24 adjusted EPS 14c-15c, consensus 13c - MSN
Myriad Genetics (NASDAQ:MYGN) Hits New 12-Month LowWhat's Next? - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Releases Q4 2024 Earnings Guidance - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Issues FY 2025 Earnings Guidance - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Releases Q4 Earnings Guidance - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Releases FY25 Earnings Guidance - MarketBeat
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance - The Manila Times
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):